TET2 and neoplasm: [28] performed whole exome sequencing of tumor samples from 486 patients in the JUPITER‐06 study [29], identifying several other favorable immunogenic features (e.g., HLA‐I/II diversity [30, 31]) and risky oncogenic alterations associated with the efficacy of chemotherapy + anti‐PD‐1 (e.g., PIK3CA [32] and TET2 mutations [33]).